High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206 SHANGHAI, June 2, 2026 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing...
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful...
TERREPOWER Demonstrates Decarbonization and Resource Efficiency at Scale in 2025 Corporate Sustainability Report
DAPHNE, Ala., May 19, 2026 /PRNewswire/ -- TERREPOWER, formerly BBB Industries, a pure‑play aftermarket leader in sustainable manufacturing, today released its 2025 Corporate Social Responsibility Report detailing measurable progress in emissions...
MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study - Japan Phase 3 results strengthen CARTISTEM's® global commercial prospects, with Japan biologics license application...
19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities
SUZHOU, China, May 7, 2026 /PRNewswire/ -- Recently, BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as "BrightGene Bio-Medical " or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP...
MOREH Demonstrates Production-Ready LLM Inference on Tenstorrent Galaxy, Achieving DGX A100-Class Performance with Improved Cost Efficiency
Reduces HBM Costs with GPU–Tenstorrent Heterogeneous Distributed Serving First unveiled at Tenstorrent's launch event, TT-Deploy, in San Francisco on May 1 SANTA CLARA, Calif., May 2, 2026 /PRNewswire/ -- Moreh, an AI infrastructure software...
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D , 600 mg QD). Phase 2 clinical outcomes include: 2L+ KRAS G12Ci–naive NSCLC: ORR of 58.8%, mPFS of 12.2 months 2L+ colorectal cancer...
Wondershare Demonstrates AI-Powered Document Workflows with PDFelement at Microsoft AI Tour Hong Kong
HONG KONG, April 23, 2026 /PRNewswire/ -- Wondershare, a global leader in digital productivity and creativity software, showcased its latest AI-powered solutions at the Microsoft AI Tour Hong Kong, highlighting how its flagship product, Wondershare...
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
HONG KONG, April 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in...
Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall response rate (ORR) of 99% WOBURN, Mass., April 13, 2026 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology and...